Project Grant F32AI191529
- This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $261,492 to Tufts University School of Medicine to study the epigenetic regulation of sporulation in Clostridioides difficile, a major nosocomial pathogen. The research aims to elucidate the role of the C. difficile-specific DNA methyltransferase CamA in mediating the epigenetic regulation of spore formation, which...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) is supporting research to develop a novel, water-soluble, cationic bolaamphiphile (CAB) platform nanocarrier complexed with an antisense oligonucleotide (ASO) targeting the essential C. difficile dnaE gene. The $426,875 award, which began on Jul 14, 2025 and runs through Jun 30, 2027, aims to advance this platform technology as a...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $136,050 to Tufts University School of Medicine to conduct research on the mechanisms that control Clostridioides difficile spore germination. The research aims to understand how C. difficile, which lacks traditional germinant receptors found in other spore-forming bacteria, uses two pseudoprotease enzymes, CspA and...
- This $233,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to optimize culture and metagenomic methods to detect multi-strain Clostridioides difficile (C. difficile) colonization and infection. The 2-year project seeks to enhance the recovery of multiple and cryptic C. difficile strains from stool samples by employing a combination of culture conditions. Additionally, the project will...
- This Project Grant award of $2,872,722 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate the role of penicillin-binding proteins (PBPs) in the Clostridioides difficile life cycle and develop new PBP inhibitors to target C. difficile sporulation. The research aims to enhance the understanding of PBPs across bacterial species and provide new insights into the unique...
- This $780,162 Project Grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at Old Dominion University from August 2022 through July 2026 exploring the role of nutrient and stress sensing in regulating Clostridioides difficile physiology and behavior within the host. The research aims to determine how the stringent response regulates disease-relevant bacterial processes and characterize enzymes that mediate alarmone metabolism...
- This $492,000 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to conduct biochemical and structural characterization of the elongasome and divisome protein complexes in Mycobacterium tuberculosis (MTB) and the model organism Mycobacterium smegmatis. The research will use bacterial genetics and endogenous protein purifications to understand how these critical protein systems coordinate and interact to...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 - Biomedical Research and Research Training program, provides $438,629 to the University of Massachusetts to characterize fundamental and conserved mechano-molecular mechanisms of cell division. The research aims to advance understanding of: 1) the functional contributions of extremely large intrinsically disordered regions (ELIDRs) in proteins at the kinetochore and perichromosomal...
- This Project Grant award, valued at $151,200.00, was issued by the Fogarty International Center (FIC) under the International Research and Research Training program (CFDA 93.989) to Mahidol University in Thailand. The award, which runs from September 16, 2025 to August 31, 2030, supports research to characterize the cyclic-di-AMP (c-di-AMP) pathway in the bacterium Clostridioides difficile. The research aims to explore the c-di-AMP pathway as a novel drug target for C. difficile, which is a...
- This $241,500 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) and dated Aug 21, 2025, supports research conducted by the University of California, Davis to accelerate microbiota recovery and restore colonization resistance against Clostridioides difficile infection. The project aims to: (1) determine whether treatment with the probiotic Anaerostipes caccae can accelerate microbiota recovery after...
DEFINING THE UNIQUE DIVISOME OF CLOSTRIDIOIDES DIFFICILE - PROJECT SUMMARY/ABSTRACT THE ESSENTIAL PROCESS OF BACTERIAL CELL DIVISION IS MEDIATED BY A MULTIPROTEIN COMPLEX CALLED THE "DIVISOME." THE DIVISOME DIRECTS PEPTIDOGLYCAN SYNTHASES TO MAKE THE SEPTAL PEPTIDOGLYCAN THAT BISECTS A BACTERIAL CELL INTO TWO DAUGHTER CELLS. RECENT PHYLOGENETIC ANALYSES INDICATE THAT THE MECHANISMS CONTROLLING CELL DIVISION - IDENTIFIED THROUGH DECADES OF WORK IN A HANDFUL OF MODEL ORGANISMS - ARE WIDELY CONSERVED AMONG BACTERIA. DESPITE THESE FINDINGS, OUR LAB RECENTLY DISCOVERED THAT THE MAJOR NOSOCOMIAL PATHOGEN CLOSTRIDIOIDES DIFFICILE MEDIATES VEGETATIVE CELL DIVISION USING A MECHANISM THAT FUNDAMENTALLY DIFFERS FROM PREVIOUSLY STUDIED BACTERIA. IN PARTICULAR, THE MAJORITY OF CORE DIVISOME PROTEINS CHARACTERIZED IN OTHER BACTERIA ARE EITHER MISSING OR DISPENSABLE FOR VEGETATIVE CELL DIVISION IN C. DIFFICILE. INDEED, C. DIFFICILE LACKS ORTHOLOGS OF THE FTSW-FTSI SEPTAL PEPTIDOGLYCAN SYNTHASE COMPLEX THAT WAS PREVIOUSLY THOUGHT TO BE UNIVERSALLY REQUIRED FOR CELL DIVISION IN BACTERIA. INSTEAD, C. DIFFICILE USES THE ENZYME PBP1, WHICH BELONGS TO A DISTINCT CLASS OF ENZYMES CALLED CLASS A PBPS, TO DRIVE SEPTAL PEPTIDOGLYCAN SYNTHESIS. GIVEN THAT C. DIFFICILE DIVISION OCCURS IN THE ABSENCE OF THE MAJORITY OF CANONICAL DIVISOME PROTEINS, THE PROTEINS THAT COMPRISE C. DIFFICILE'S UNIQUE DIVISOME AND THUS GOVERN PBP1 RECRUITMENT TO THE SITE OF DIVISION AND LICENSE ITS SEPTAL PEPTIDOGLYCAN SYNTHASE ACTIVITY REMAIN UNKNOWN. TO ADDRESS THIS CRITICAL GAP IN KNOWLEDGE, THIS PROPOSAL SEEKS TO IDENTIFY AND CHARACTERIZE C. DIFFICILE'S UNIQUE CELL DIVISION MACHINERY AND TO DETERMINE THE ORDER OF ASSEMBLY OF THIS NOVEL COMPLEX. I WILL EMPLOY A FORWARD GENETIC SELECTION, AS WELL AS A COMPLEMENTARY CANDIDATE-BASED SCREENING APPROACH, TO IDENTIFY NEW ESSENTIAL CELL DIVISION GENES. IN PARALLEL, I WILL BIOCHEMICALLY DEFINE THE DIVISOME COMPLEX BY IDENTIFYING PROTEINS THAT INTERACT WITH ONE OF THREE KNOWN CORE DIVISOME COMPLEX PROTEINS IN C. DIFFICILE. TO DELINEATE THE ORDER OF ASSEMBLY, I WILL LEVERAGE FLUORESCENT PROTEIN FUSIONS AND GENETIC KNOCK-DOWNS TO DETERMINE THE LOCALIZATION DEPENDENCIES OF DIVISOME PROTEIN CANDIDATES. THESE ANALYSES WILL THUS UNCOVER CRITICAL COMPONENTS OF THE C. DIFFICILE DIVISION MACHINERY AND DELINEATE HOW THEY ASSEMBLE INTO A FUNCTIONAL DIVISOME. BY PROVIDING NOVEL INSIGHT INTO C. DIFFICILE'S DIVISION MECHANISM, THE PROPOSED ANALYSES WILL ALSO HIGHLIGHT THAT THERE IS GREATER DIVERSITY IN BACTERIAL CELL DIVISION MECHANISMS THAN PREVIOUSLY THOUGHT BASED ON MODEL SYSTEMS. BY IDENTIFYING UNIQUE FACTORS THAT ARE ESSENTIAL FOR C. DIFFICILE CELL DIVISION, THIS WORK WILL ULTIMATELY FACILITATE THE DEVELOPMENT OF C. DIFFICILE-SPECIFIC THERAPIES THAT SPARE THE COMMENSAL GUT FLORA. SUCH C. DIFFICILE-SPECIFIC THERAPIES ARE CRITICALLY NEEDED GIVEN THAT THE MOST EFFECTIVE THERAPIES FOR TREATING C. DIFFICILE INFECTIONS ARE THOSE THAT PRESERVE THE NATIVE GUT MICROBIOTA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $75.5k | 7/1/25 |